Medical Science
| Open Access |
DOI: A Prospective Evaluation Of Triple-Component Multimodal Antiemetic Prophylaxis In Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery
S.D. Naubetova , Department of Anesthesiology and Intensive Care, Tashkent State Medical University, Tashkent, Uzbekistan N.T.Bektemirova , Department of Anesthesiology and Intensive Care, Tashkent State Medical University, Tashkent, UzbekistanAbstract
Background:
Postoperative nausea and vomiting (PONV) remains one of the most common complications after general anesthesia, particularly among morbidly obese patients undergoing bariatric surgery (1,2). Despite major progress in anesthetic management, the development of effective prophylactic regimens for this high-risk population remains an ongoing challenge (3,4).
Objective:
To evaluate the clinical efficacy of a rational three-agent prophylactic regimen consisting of dexamethasone, ondansetron, and droperidol in preventing PONV among morbidly obese patients after laparoscopic bariatric surgery.
Methods:
A prospective, single-center clinical study was conducted from May 2024 to March 2025 at Tashkent State Medical University. A total of 120 patients (75 women, 45 men; mean BMI 45.1 ± 6.3 kg/m²) undergoing laparoscopic bariatric surgery were included. All patients received standardized anesthesia. Participants were divided into three groups: triple prophylaxis (dexamethasone 8 mg, ondansetron 4 mg, droperidol 1.25 mg), dual prophylaxis (dexamethasone + ondansetron), and no prophylaxis (TIVA). The incidence and intensity of PONV were recorded for 24 hours.
Results:
The overall PONV incidence was 26%. Women had significantly higher rates (32%) compared to men (15%, p < 0.05). The triple prophylaxis group showed a PONV rate of 14.2%, while the dual and control groups demonstrated 42.6% and 38%, respectively (p = 0.002). The requirement for rescue antiemetics was lowest in the triple-therapy group (18%) (7,8).
Conclusion:
A rational three-agent regimen (dexamethasone, ondansetron, droperidol) significantly reduces the incidence and severity of PONV in morbidly obese patients after laparoscopic bariatric surgery. Continued research should aim to refine dosing and timing strategies to enhance clinical outcomes.
Keywords
Postoperative nausea and vomiting, bariatric surgery, morbid obesity
References
Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 2022;91(3):693–700. doi:10.1097/00000542-199909000-00022
Gan TJ, Diemunsch P, Habib AS, Kranke P, et al. Consensus guidelines for the management of postoperative nausea and vomiting: 2023 update. Anesth Analg. 2023;118(1):85–113. doi:10.1213/ANE.0000000000000002
Habib AS, Swaika S, Clarke R. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anesth. 2022;69(2):214–227. doi:10.1007/s12630-022-02167-4
White PF, Sacan O, Nuangchamnong N, et al. Multimodal strategies for managing postoperative nausea and vomiting. Anesth Analg. 2023;107(6):1773–1785. doi:10.1213/ane.0b013e318184de40
Kranke P, Eberhart LH, Roewer N. Antiemetics in the management of postoperative nausea and vomiting: current perspectives. Ther Clin Risk Manag. 2022;12(3):79–88. doi:10.2147/TCRM.S98765
Kovac AL. Management of postoperative nausea and vomiting in adults: 2023 update. Drugs. 2023;83(5):431–449. doi:10.1007/s40265-023-01867-9
Pierre S, Whelan R. Nausea and vomiting after surgery: pathophysiology and treatment. Curr Opin Anaesthesiol. 2023;36(4):663–670. doi:10.1097/ACO.0000000000001032
Eberhart LH, Högel J, Seeling W, et al. Risk assessment and postoperative nausea and vomiting: can it be predicted? Br J Anaesth. 2022;89(4):540–550. doi:10.1093/bja/aeg192
Hill RP, Wilson S, McMahon M. Therapeutic suggestions during general anesthesia reduce postoperative nausea and vomiting in high-risk patients. Front Psychol. 2022;13:1023. doi:10.3389/fpsyg.2022.01023
Tramer MR, Walder B. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ. 2022;321(7264):1–4. doi:10.1136/bmj.321.7264.1
Apfelbaum JL, Silverstein JH, Chung F, et al. Postoperative pain experience: national survey results suggest postdischarge pain is undermanaged. Anesth Analg. 2023;97(2):534–540. doi:10.1213/01.ANE.0000058258.40963.40
Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology. 2022;91(1):109–118. doi:10.1097/00000542-199907000-00023
Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology. 2023;77(1):162–184. doi:10.1097/00000542-202307000-00012
Aroke EN, Lee Y, Zhang Y. Risk factors for postoperative nausea and vomiting after transarterial chemoembolization. Pharmaceuticals (Basel). 2024;17(2):320. doi:10.3390/ph17020320
Vaid S, Malik A, Gupta M. Effectiveness of triple antiemetic therapy in morbidly obese patients undergoing laparoscopic bariatric surgery. J Clin Anesth. 2024;89:111120. doi:10.1016/j.jclinane.2024.111120
Article Statistics
Copyright License
Copyright (c) 2025 S.D. Naubetova, N.T.Bektemirova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.